HDACi: Molecular mechanisms and therapeutic implications in the innate immune system

Immunology and Cell Biology

Volumn 90, Issue 1, 2012, Pages 23-32

  Suliman, Bandar Ali ^a,b   Xu, Dakang ^b   Williams, Bryan R G ^b  

^a TAIBAH UNIVERSITY   (Saudi Arabia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

acetylation; chromatin; HDAC; histones; innate immunity

Indexed keywords

BELINOSTAT; BUTYRIC ACID; DACINOSTAT; ENTINOSTAT; FR 276457; GAMMA INTERFERON; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA1; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 6; MOCETINOSTAT; PANOBINOSTAT; PROTEIN BAX; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTIINFLAMMATORY ACTIVITY; CANCER CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVITY; HISTONE ACETYLATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; MODELS, IMMUNOLOGICAL;

EID: 84855464229     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2011.92     Document Type: Review

References (113)

1. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-352. (Pubitemid 27415209)
2. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993; 72: 73-84. (Pubitemid 23029694)
3. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002; 108: 475-487. (Pubitemid 34260873)
4. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21. (Pubitemid 34049633)
5. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45. (Pubitemid 30038513)
6. Davey CA, Sargent DF, Luger K, Maeder AW, Richmond TJ. Solvent mediated interactions in the structure of the nucleosome core particle at 1.9A resolution. J Mol Biol 2002; 319: 1097-1113. (Pubitemid 34729421)
7. Reinke H, Horz W. Histones are first hyperacetylated and then lose contact with the activated PHO5 promoter. Mol Cell 2003; 11: 1599-1607. (Pubitemid 36776545)
8. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998; 12: 599-606. (Pubitemid 28134293)
9. Galarneau L, Nourani A, Boudreault AA, Zhang Y, Héliot L, Allard S et al. Multiple links between the Nu A4 histone acetyltransferase complex and epigenetic control of transcription. Mol Cell 2000; 5: 927-937.
10. Brown KE, Guest SS, Smale ST, Hahm K, Merkenschlager M, Fisher AG. Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochroma-tin. Cell 1997; 91: 845-854. (Pubitemid 28007740)
11. Wade PA, Pruss D, Wolffe AP. Histone acetylation: chromatin in action. Trends Biochem Sci 1997; 22: 128-132. (Pubitemid 27156942)
12. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40: 1-13. (Pubitemid 40092373)
13. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltrans-ferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279: 51163-51171. (Pubitemid 40017859)
14. Marks P, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009; 107: 600-608.
15. Maier T, Beckers T, Hummel R, Feth M, Muller M, Bar T et al. Novel sulphonylpyrroles as inhibitors of Hdac S novel sulphonylpyrroles. US Patent App. 20,090/263,353; 2006.
16. Host L, Dietrich JB, Carouge D, Aunis D, Zwiller J. Cocaine self-administration alters the expression of chromatin-remodelling proteins; modulation by histone deacetylase inhibition. JPsychopharmacol 2011; 25: 222-229.
17. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J et al. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol 2011; 186: 3986-3996.
18. Song W, Tai YT, Tian Z, Hideshima T, Chauhan D, Nanjappa P et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011; 25: 161-168.
19. Qian X, La Rochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006; 5: 2086-2095. (Pubitemid 44336581)
20. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008; 7: 759-768. (Pubitemid 351551029)
21. Vaughan EE, Geiger RC, Miller AM, Loh-Marley PL, Suzuki T, Miyata N et al. Microtubule acetylation through HDAC6 inhibition results in increased transfection efficiency. Mol Ther 2008; 16: 1841-1847.
22. Guardiola AR, Yao T-P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J Biol Chem 2002; 277: 3350-3356. (Pubitemid 34953202)
23. Zhang Z, Zhang Z, Schluesener H. MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 2010; 169: 370-377.
24. Lu A, Luo H, Shi M, Wu G, Yuan Y, Liu J et al. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors. Bioorg Med Chem Lett 2011; 21: 4924-4927.
25. Kinugasa F, Nagatomi I, Nakanishi T, Noto T, Mori H, Matsuoka H et al. Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl Immunol 2009; 21: 198-202.
26. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2007; 409: 581-589.
27. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005; 96: 293-304. (Pubitemid 41437862)
28. Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011; 29: 255-265.
29. Masumoto H, Hawke D, Kobayashi R, Verreault A. A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature 2005; 436: 294-298. (Pubitemid 41021284)
30. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
31. Bernstein BE, Tong JK, Schreiber SL. Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA 2000; 97: 13708-13713.
32. Weems J, Olson AL. Class II histonedeacetylases limit GLUT4 geneexpression during adipocyte differentiation. J Biol Chem 2011; 286: 460-468.
33. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histonedeacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
34. Isomäki P, Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 1997; 29: 499-507. (Pubitemid 28135102)
35. Adcock I. HDAC inhibitors as anti inflammatory agents. Br J Pharmacol 2007; 150: 829-831. (Pubitemid 46536629)
36. Hackett CJ, Rotrosen D, Auchincloss H, Fauci AS. Immunology research: challenges and opportunities in a timeof budgetaryconstraint. Nat Immunol 2007; 8: 114-117. (Pubitemid 46152637)
37. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995-3000. (Pubitemid 34240574)
38. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest 2003; 111: 539-552. (Pubitemid 36228011)
39. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler Tet al. Histonedeacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117: 1205-1217.
40. Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patientswithadvanced solidtumors. Clin Cancer Res 2008; 14: 804-810. (Pubitemid 351231163)
41. El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NH et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010; 9: 1349-1360.
42. Maa M-C, Chang MY, Hsieh M-Y, Chen Y-J, Yang C-J, Chen Z-C et al. Butyrate reduced lipopolysaccharide-mediated macrophage migration by suppression of Src enhance-ment and focal adhesion kinase activity. J Nutr Biochem 2010; 21: 1186-1192.
43. Kim H-S, Whang S-Y, Woo M-S, Park J-S, Kim W-K, Han I-O. Sodium butyrate suppresses interferon-gamma-, but not lipopolysaccharide-mediated induction of nitric oxide and tumor necrosis factor-alpha in microglia. J Neuroimmunol 2004; 151: 85-93. (Pubitemid 38624403)
44. Säemann MD, Böhmig GA, Österreicher CH, Burtscher H, Parolini O, Diakos C et al. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 2000; 14: 2380-2382.
45. Nencioni A, Beck J, Werth D, Grünebach F, Patrone F, Ballestrero A et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007; 13: 3933-3941. (Pubitemid 47037601)
46. Khaskhely N, Buglio D, Shafer J, Bollard C, Younes A. Thehistonedeacetylase(HDAC) inhibitor entinostat (SNDX-275) targets Hodgkin lymphoma through a dual mechan-ism of immune modulation and apoptosis induction. Blood (ASH Annual Meeting Abstracts) 2009; 114: 1562.
47. Ichiyama T, Okada K, Lipton JM, Matsubara T, Hayashi T, Furukawa S. Sodium valproate inhibits production of TNF-[alpha] and IL-6 and activation of NF-[kappa]B. Brain Res 2000; 857: 246-251. (Pubitemid 30107811)
48. Kochanek AR, Fukudome EY, Li Y, Smith EJ, Liu B, Velmahos GC et al. Histone deacetylase inhibitor treatment attenuates MAP kinase pathway activation and pulmonary inflammation following hemorrhagic shock in a rodent model. JSurg Res 2011 (in press; doi:10.1016/j.jss. 2011.06.007).
49. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109: 1123-1130. (Pubitemid 46220659)
50. Golay J, Cuppini L, Leoni F, Mico C, Barbui V, Domenghini M et al. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007; 21: 1892-1900. (Pubitemid 47299961)
51. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani Pet al.The hist one deacety lase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005; 11: 1-15.
52. Ospelt C, Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol 2010; 42: 495-505.
53. Takami M, Terry V, Petruzzelli L. Signaling pathways involved in IL-8-dependent activation of adhesion through Mac-1. J Immunol 2002; 168: 4559-4566. (Pubitemid 34441361)
54. Merz D, Liu R, Johnson K, Terkeltaub R. IL-8/CXCL8 and growth-related oncogene/ CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol 2003; 171: 4406-4415. (Pubitemid 37238720)
55. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho Tet al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324-329. (Pubitemid 35398188)
56. Baines KJ, Simpson JL, Gibson PG. Innate immune responses are increased in chronic obstructive pulmonary disease. PLo S ONE 2011; 6: e18426.
57. Roelofs M. Expression of Toll-like receptor (TLR) 2, TLR3, TLR4 and TLR7 is increased in rheumatoid arthritis synovium and regulates cytokine production by dendritic cells upon stimulation of TLR specific pathways. Arthritis Res Ther 2005; 7: P70.
58. So EY, Kim BS. Theiler's virus infection induces TLR3-dependent upregulation of TLR2 critical for proinflammatory cytokine production. Glia 2009; 57: 1216-1226.
59. Pennini ME, Pai RK, Schultz DC, Boom WH, Harding CV. Mycobacterium tuberculosis 19-k Da lipoprotein inhibits IFN-gamma-induced chromatin remodelingof MHC2TAby TLR2 and MAPK signaling. J I mm unol 2006; 176: 4323-4330. (Pubitemid 44264411)
60. Schauber J, Dorschner RA, Coda AB, Buchau A, Liu PT, Kiken D et al. Injuryenhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 2007; 117: 803-811. (Pubitemid 46348539)
61. Schauber J, Oda Y, Buchau AS, Yun Q-C, Steinmeyer A, Zugel U et al. Histone acetylation in keratinocytesenablescontrol of theexpression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. JInvest Dermatol 2007; 128: 816-824. (Pubitemid 351374298)
62. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 2002; 23: 375-378. (Pubitemid 34804626)
63. Farina GA, York MR, Di Marzio M, Collins CA, Meller S, Homey B et al. Poly(I:C) drivestype I IFN- and TGF[beta]-mediated inflammation and dermal fibrosis simulat-ing altered gene expression in systemic sclerosis. J Invest Dermatol 2010; 130: 2583-2593.
64. Kuwata T, Gongora C, Kanno Y, Sakaguchi K, Tamura T, Kanno T et al. Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element. Mol Cell Biol 2002; 22: 7439-7448.
65. Fragale A, Stellacci E, Ilari R, Remoli AL, Lanciotti A, Perrotti E et al. Critical roleof IRF-8 in negative regulation of TLR3 expression by Src Homology 2 domain-contain-ing protein tyrosine phosphatase-2 activity in human myeloid dendritic cells. JImmunol 2011; 186: 1951-1962.
66. Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, Cogen AL et al. Commensal bacteria regulate Toll-like receptor3-dependent inflammation after skin injury. Nat Med 2009; 15:1377-1382.
67. Gilmore T. Introduction to NF-κB: players, pathways, perspectives. Oncogene 2006; 25: 6680-6684. (Pubitemid 44657845)
68. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-bindingprotein/ p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997; 94: 2927-2932. (Pubitemid 27157241)
69. Chen L, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-κB action regulated byreversibleacetylation. Science 2001; 293: 1653-1657. (Pubitemid 32807844)
70. Pahl HL. Activators and target genes of Rel/NF-kappa B transcription factors. Onco-gene 1999; 18: 6853-6866.
71. Hu J, Colburn NH. Histone deacetylase inhibition down-regulates cyclin D1 transcrip-tion by inhibiting nuclear factor-?B/p65 DNA binding. Mol Cancer Res 2005; 3: 100-109. (Pubitemid 40271140)
72. Smale ST. Hierarchies of NF-[kappa]B target-gene regulation. Nat Immunol 2011; 12: 689-694.
73. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-1123.
74. Darnell J, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264: 1415-1421. (Pubitemid 24217131)
75. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci 2004; 117: 1281-1283. (Pubitemid 38559804)
76. Kimura T, Kadokawa Y, Harada H, Matsumoto M, Sato M, Kashiwazaki Y et al. Essential and non-redundant roles of p48 (ISGF3γ) and IRF-1 in both type I and type II interferon responses, as revealed bygenetargeting studies. Genes Cells 1996; 1: 115-124. (Pubitemid 126673111)
77. Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 2003; 100: 14742-14747. (Pubitemid 37517961)
78. Klampfer L, Huang J, Swaby L-A, Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. J Biol Chem 2004; 279: 30358-30368. (Pubitemid 38937963)
79. Chang H-M, Paulson M, Holko M, Rice CM, Williams BRG, Marié I et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 2004; 101: 9578-9583. (Pubitemid 38869278)
80. Xu D, Holko M, Sadler AJ, Scott B, Higashiyama S, Berkofsky-Fessler W et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 2009; 30: 802-816.
81. Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev 2004; 15: 435-455. (Pubitemid 39550454)
82. Mc Whirter SM, Fitzgerald KA, Rosains J, Rowe DC, Golenbock DT, Maniatis T. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci USA 2004; 101: 233-238. (Pubitemid 38084233)
83. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595-596.
84. Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000; 19: 2468-2473. (Pubitemid 30339202)
85. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-954. (Pubitemid 35177340)
86. Kanneganti T-D, Lamkanfi M, Núñez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007; 27: 549-559. (Pubitemid 47615512)
87. Kim JG, Lee SJ, Kagnoff MF. Nod1 is an essential signal transducer in intestinal epithelial cells infected with bacteria that avoid recognition by toll-like receptors. Infect Immun 2004; 72: 1487-1495. (Pubitemid 38263771)
88. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Núñez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-κB. J Biol Chem 2001; 276:4812-4818.
89. Radford-Smith G, Pandeya N. Associations between NOD2/CARD15 genotype and phenotype in Crohn's disease-Are we there yet? World J Gastroenterol 2006; 12: 7097-7103. (Pubitemid 44890637)
90. Kim TH, Payne U,Zhang X, Iwanaga Y, Davey MP, Rosenbaum JTet al.Alteredhost: pathogen interactions conferred by the Blau syndrome mutation of NOD2. Rheumatol Int 2007; 27: 257-262. (Pubitemid 46088255)
91. Cummings J, Pomare E, Branch W, Naylor C, Macfarlane G. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 1987; 28: 1221-1227. (Pubitemid 17156038)
92. Leung C-H, Lam W, Ma D-L, Gullen EA, Cheng Y-C. Butyrate mediates nucleotide-binding and oligomerisation domain (NOD) 2-dependent mucosal immune responses against peptidoglycan. Eur JImmunol 2009; 39: 3529-3537.
93. Joosten LAB, Leoni F, Meghji S, Mascagni P. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol Med 2011; 17: 391-396.
94. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHCclass II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-146.
95. Leibund Gut Landmann S, Waldburger JM, Krawczyk M, Otten LA, Suter T, Fontana A et al. Mini review: specificity and expression of CIITA, the master regulator of MHC class II genes. Eur JImmunol 2004; 34: 1513-1525. (Pubitemid 39256032)
96. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differ-ential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16: 2851-2860. (Pubitemid 27226221)
97. Wang Y,Curry HM,Zwilling BS, Lafuse WP. Mycobacteria inhibition of IFN-γ induced HLA-DR gene expression by up-regulating histone deacetylation at the promoter region in human THP-1 monocytic cells. J Immunol 2005; 174: 5687-5694. (Pubitemid 40593211)
98. Kong X, Fang M, Li P, Fang F, Xu Y HDAC2 deacetylates class II transactivator and suppresses its activity in macrophages and smooth muscle cells. J Mol Cell Cardiol 2009; 46: 292-299.
99. Mc Kinsey TA, Kuwahara K, Bezprozvannaya S, Olson EN. Class II histone deacety-lases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK. Mol Biol Cell 2006; 17: 438-447. (Pubitemid 43049495)
100. Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O'Garra A. Interleukin-10 production by Th1 cells requires interleukin-12-induced STAT4 tran-scription factor and ERK MAP kinase activation by high antigen dose. Immunity 2009; 31: 209-219.
101. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
102. Gazzaniga S, Bravo AI, Guglielmotti A, Van Rooijen N, Maschi F, Vecchi A et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogen-esisandtumorgrowth in a human melanomaxenograft. JInvest Dermatol 2007; 127: 2031-2041. (Pubitemid 47075380)
103. Kim S, Takahashi H, Lin W-W, Descargues P, Grivennikov S, Kim Yet al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-106.
104. Huang B, Zhao J, Shen S, Li H, He K-L, Shen G-X et al. Listeria monocytogenes promotestumorgrowth viatumorcell Toll-likereceptor 2 signaling. Cancer Res 2007; 67: 4346-4352. (Pubitemid 46815083)
105. Xu K, Ding Q, Fang Z, Zheng J, Gao P, Lu Y et al. Silencing of HIF-1 suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis. Cancer Gene Ther 2009; 17: 212-222.
106. Le QT, Courter D, Giaccia A. Hypoxia, angiogenesis, and oral cancer metastasis. In: Mayers J, (ed). Oral Cancer Metastasis: Springer; 2009. pp 299-321.
107. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M et al. Expression of hypoxia-induciblefactor 1 [alpha], hypoxia-induciblefactor2 [alpha], andvon Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1 [alpha] is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007; 38: 1310-1320. (Pubitemid 47247486)
108. Nicholas SA, Sumbayev VV. The role of redox-dependent mechanisms in the down-regulation of ligand-induced Toll-like receptors 7, 8 and 4-mediated HIF-1 prolyl hydroxylation. Immunol Cell Biol 2009; 88: 180-186.
109. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histonedeacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010; 3: 5.
110. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacety-lases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202. (Pubitemid 33741894)
111. Kucine N, Levine RL. JAK inhibitors and other novel agents in myeloproliferative neoplasms: arewe hittingthetarget? Ther Adv Hematol 2011; 4: 203-211.
112. Reddy P, Sun Y, Toubai T, Duran-Struuck R, Clouthier SG, Weisiger E et al. Histone deacetylase inhibition modulates indoleamine 2, 3-dioxygenase- dependent DC func-tions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008; 118: 2562-2573. (Pubitemid 351949783)
113. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine2,3-dioxygenase. Nat Med 2003; 9: 1269-1274. (Pubitemid 37279849)